Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Ain Shams University
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06201663CT.gov Romiplostim in Chemotherapy-Induced Thrombocytopenia | — | Unknown | — | — | — |
NCT04673266CT.gov Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma | — | Completed | — | — | — |
NCT03937154CT.gov Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03362177CT.gov Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | — | Completed | — | — | — |
NCT03343847CT.gov Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma. | — | Withdrawn | — | — | — |
NCT02227576CT.gov Prevention of Thrombocytopenia in Glioblastoma Patients | — | Terminated | — | — | — |
NCT01676961CT.gov Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy | — | Terminated | — | — | — |
NCT00413283CT.gov Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00283439CT.gov A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Thrombocytopenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Romiplostim (this asset) | Ain Shams University | P3 | BB · 65 |
| Recombinant Human Thrombopoietin | Sun Yat-sen University | P4 | BBB |
| Eltrombopag | Institute of Hematology & Blood Diseases Hospital, China | P4 | BB |
| Nivestim | OHSU Knight Cancer Institute | P2 | BB |
| Avatrombopag | Second Affiliated Hospital of Guangzhou Medical University | P4 | BB |
| Hetrombopag | Sun Yat-sen University | P3 | BB |
| Cytarabine | OHSU Knight Cancer Institute | P2 | BB |
| Cyclosporin A | Children's Hospital Los Angeles | P2 | BB |
| PN-152,243 | Pfizer | P3 | BB |
+42 more in the Thrombocytopenia cohort
Other indications for Romiplostim
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P2 | B · 59 |
| Cancer | — | P3 | B · 56 |
| Neoplasm | — | P2 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Romiplostim in Thrombocytopenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/romiplostim-thrombocytopenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →